. Author manuscript; available in PMC: 2010 Sep 2.

Published in final edited form as: Ann Oncol. 2008 Feb 1;19(5):915–919. doi: 10.1093/annonc/mdm599

Table 1.

Associations between low TS, DPD and TP expression and clinicopathological and molecular features of stages II and III CRC

Feature	Tumours with low expression levels (%)
Feature	TS	DPD	TP
Total	581/945 (61)	296/858 (34)	367/942 (39)
Male	296/473 (63)	145/426 (34)	186/465 (40)
Female	285/472 (60)	151/432 (35)	181/477 (38)
<70 years	288/455 (63)	156/413 (38)	177/451 (39)
≥70 years	293/490 (60)	140/445 (30)	190/491 (39)
Stage II	344/587 (59)	138/506 (27)	233/584 (40)
Stage III	237/358 (66)	158/352 (45)	134/358 (37)
	P = 0.020	P < 0.0001
Distal colon/rectum	338/509 (66)	156/466 (33)	213/511 (42)
Proximal colon	215/390 (55)	125/357 (35)	139/388 (36)
	P = 0.0005
Well differentiated	95/156 (61)	45/132 (34)	60/159 (38)
Moderately differentiated	237/388 (61)	110/341 (32)	152/381 (40)
Poorly differentiated	46/88 (52)	27/73 (37)	35/89 (39)

CRC, colorectal cancer; TS, thymidylate synthase; DPD, dihydropyrimidine dehydrogenase; TP, thymidine phosphorylase.